Media
Almost two years after phase 3 results on the leading COVID-19 vaccines started rolling in, Providence Therapeutics has posted midphase data on its mRNA candidate and outlined plans to move into a pivotal booster study.
Almost two years after phase 3 results on the leading COVID-19 vaccines started rolling in, Providence Therapeutics has posted midphase data on its mRNA candidate and outlined plans to move into a pivotal booster study.